12:50 PM EDT, 05/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target by $3 to $75, 15.4x our 2025 EPS estimate of $4.86 (down $0.02), a discount to HSIC's five-year historical forward average of 17.2x. We lower our 2026 EPS estimate by $0.07 to $5.27. Though we do not anticipate HSIC will face significant tariff-related pressures given its deep industry scale and ability to pass-through price increases, we think the underlying dental and medical product distribution market remains challenged by macro pressures and inconsistent results across different countries. HSIC's restructuring efforts appear to be supporting margin improvement, and we think the recent KKR investment and board representation should enhance focus on extracting better shareholder value from HSIC's strong market positioning. We maintain our Hold view and continue to see more attractive fundamental trends among pharmaceutical product distributors compared to their non-pharma peers.